Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause

Gebhart, 2018, High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB), Haemophilia, 24, 405, 10.1111/hae.13422 Quiroga, 2012, Is my patient a bleeder? A diagnostic framework for mild bleeding disorders, Hematol Am Soc Hematol Educ Progr, 2012, 466, 10.1182/asheducation.V2012.1.466.3798741 Mezzano, 2018, Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research, J Thromb Haemost 2003, KG Thrombin formation, Chest, 124, 4S, 10.1378/chest.124.3_suppl.4S Hemker, 2003, Calibrated automated thrombin generation measurement in clotting plasma, Pathophysiol Haemost Thromb, 33, 4, 10.1159/000071636 Rugeri, 2007, Thrombin‐generating capacity in patients with von Willebrand's disease, Haematologica, 92, 1639, 10.3324/haematol.11460 Van Veen, 2008, Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A, Thromb Res, 123, 895, 10.1016/j.thromres.2008.09.011 Dargaud, 2005, Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B, Thromb Haemost, 93, 475, 10.1160/TH04-10-0706 Antovic, 2013, Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand, Thromb Haemost, 111, 656 Ay, 2011, Thrombin generation in patients with a bleeding tendency of unknown origin, Ann Hematol, 90, 1099, 10.1007/s00277-011-1201-8 Undas, 2010, Fibrin clot properties in acute ischemic stroke: relation to neurological deficit, Thromb Res, 125, 357, 10.1016/j.thromres.2009.11.013 Okraska‐Bylica, 2012, Altered fibrin clot properties in patients with premature peripheral artery disease, Pol Arch Med Wewnętrznej, 122, 608 Undas, 2009, Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives, Blood, 114, 4272, 10.1182/blood-2009-05-222380 Undas, 2014, Fibrin clot properties and their modulation in thrombotic disorders, Thromb Haemost, 112, 32, 10.1160/TH14-01-0032 Brummel‐Ziedins, 2009, Discordant fibrin formation in hemophilia, J Thromb Haemost, 7, 825, 10.1111/j.1538-7836.2009.03306.x Gray, 2011, Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q‐FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma, Thromb Res, 128, 570, 10.1016/j.thromres.2011.04.009 He, 2003, The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX, J Thromb Haemost, 1, 1215, 10.1046/j.1538-7836.2003.00242.x Gebhart, 2015, Plasma clot properties in patients with a mild‐to‐moderate bleeding tendency of unknown cause, Ann Hematol, 94, 1301, 10.1007/s00277-015-2399-7 Rodeghiero, 2005, The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study, J Thromb Haemost, 3, 2619, 10.1111/j.1538-7836.2005.01663.x Bowman, 2017, Bleeding scores for the diagnosis of von Willebrand disease, Semin Thromb Hemost, 43, 530, 10.1055/s-0036-1597289 Leebeek, 1988, Mild haemostatic problems associated with congenital heterozygous alpha 2‐antiplasmin deficiency, Thromb Haemost, 59, 96, 10.1055/s-0038-1646773 Carpenter, 2008, α2‐antiplasmin and its deficiency: fibrinolysis out of balance, Haemophilia, 14, 1250, 10.1111/j.1365-2516.2008.01766.x Haslacher, 2018, Usage data and scientific impact of the prospectively established fluid bioresources at the hospital‐based MedUni Wien Biobank, Biopreserv Biobank, 16, 477, 10.1089/bio.2018.0032 Wolberg, 2005, High dose factor VIIa improves clot structure and stability in a model of haemophilia B, Br J Haematol, 131, 645, 10.1111/j.1365-2141.2005.05820.x Pieters, 2018, An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH, J Thromb Haemost, 16, 1007, 10.1111/jth.14002 Moenen, 2018, The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: a systematic review, Haemophilia, 24, 525, 10.1111/hae.13486 Martinelli, 1998, Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families, Blood, 92, 2353, 10.1182/blood.V92.7.2353 Dargaud, 2015, Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation, Blood, 125, 1497, 10.1182/blood-2014-10-604553 LM, 2013, Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα, J Clin Invest, 123, 3777, 10.1172/JCI69091 Cunha, 2015, A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function, Blood, 125, 1822, 10.1182/blood-2014-08-592733 Kuang, 2001, Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas, Blood, 97, 1549, 10.1182/blood.V97.6.1549 de Bosch, 2002, Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I), Thromb Haemost, 88, 253, 10.1055/s-0037-1613195 Omarova, 2013, Inhibition of thrombin‐mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ’, J Thromb Haemost, 11, 1669, 10.1111/jth.12354 P, 2015, Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case‐control study. Garcia de Frutos P, editor, PLoS ONE, 10, e0125069, 10.1371/journal.pone.0125069 Gebhart, 2017, Fibrinolysis in patients with a mild‐to‐moderate bleeding tendency of unknown cause, Ann Hematol, 96, 489, 10.1007/s00277-016-2893-6 Leminen, 2012, Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety, Int J Womens Health, 4, 413 Zahed, 2013, A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial, Am J Emerg Med, 31, 1389, 10.1016/j.ajem.2013.06.043 Rydz, 2012, Approach to the diagnosis and management of common bleeding disorders, Semin Thromb Hemost, 38, 711, 10.1055/s-0032-1326783